RhumbLine Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
|
|||||
|
2023
Q2 | $4.9M | Buy |
|
|||||
|
2023
Q1 | $3.67M | Buy |
|
|||||
|
2022
Q4 | $1.48M | Buy |
|
|||||
|
2022
Q3 | $958K | Buy |
|
|||||
|
2022
Q2 | $1.06M | Buy |
|
|||||
|
2022
Q1 | $982K | Sell |
|
|||||
|
2021
Q4 | $792K | Sell |
|
|||||
|
2021
Q3 | $3.06M | Buy |
|
|||||
|
2021
Q2 | $4.27M | Buy |
|
|||||
|
2021
Q1 | $2.53M | Sell |
|
|||||
|
2020
Q4 | $3.21M | Sell |
|
|||||
|
2020
Q3 | $2.53M | Sell |
|
|||||
|
2020
Q2 | $4.34M | Sell |
|
|||||
|
2020
Q1 | $5.52M | Buy |
|
|||||
|
2019
Q4 | $7.18M | Buy |
|
|||||
|
2019
Q3 | $2.51M | Buy |
|
|||||
|
2019
Q2 | $2.78M | Buy |
|
|||||
|
2019
Q1 | $2.14M | Buy |
|
|||||
|
2018
Q4 | $1.4M | Buy |
|
|||||
|
2018
Q3 | $1.37M | Buy |
|
|||||
|
2018
Q2 | $538K | Buy |
|
|||||
|
2018
Q1 | $211K | Buy |
|
|||||
|
2017
Q4 | $285K | Buy |
|
|||||
|
2017
Q3 | $309K | Buy |
|
|||||
|
2017
Q2 | $303K | Buy |
|